A detailed history of Rinkey Investments transactions in Bio Atla, Inc. stock. As of the latest transaction made, Rinkey Investments holds 25,310 shares of BCAB stock, worth $43,533. This represents 0.01% of its overall portfolio holdings.

Number of Shares
25,310
Previous 25,310 -0.0%
Holding current value
$43,533
Previous $34,000 29.41%
% of portfolio
0.01%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$1.37 - $3.92 $34,674 - $99,215
25,310 New
25,310 $34,000
Q4 2023

Feb 12, 2024

BUY
$1.27 - $3.18 $32,143 - $80,485
25,310 New
25,310 $62,000
Q2 2023

Aug 10, 2023

BUY
$2.83 - $3.87 $283 - $387
100 Added 0.4%
25,310 $75,000
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $5,292 - $21,366
1,800 Added 7.69%
25,210 $226,000
Q2 2022

Aug 09, 2022

BUY
$2.13 - $5.38 $49,863 - $125,945
23,410 New
23,410 $76,000
Q1 2022

May 09, 2022

SELL
$4.38 - $18.78 $43 - $187
-10 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$19.0 - $30.95 $190 - $309
10 New
10 $0

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $62.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Rinkey Investments Portfolio

Follow Rinkey Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rinkey Investments, based on Form 13F filings with the SEC.

News

Stay updated on Rinkey Investments with notifications on news.